| Bioactivity | Etoposide-d3 (VP-16-d3) is the deuterium labeled Etoposide (HY-13629). Etoposide (VP-16) is an anti-cancer chemotherapy agent. Etoposide inhibits topoisomerase II, thus stopping DNA replication. Etoposide induces cell cycle arrest, apoptosis and autophagy[1]. |
| Formula | C29H29D3O13 |
| Molar Mass | 591.58 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Hande KR, et al. The Importance of Drug Scheduling in Cancer Chemotherapy: Etoposide as an Example. Oncologist. 1996;1(4):234-239. [2]. Calvani M, det al. Etoposide-Anti-Human VEGF a new strategy against human melanoma cells expressing stem-like traits. Oncotarget. 2016 Jun 9. doi: 10.18632/oncotarget.9939. [3]. Fuchs, J., et al. Comparative activity of NSC 119875, NSC 109724, NSC 123127, NSC 241240, and etoposide in heterotransplanted hepatoblastoma. Cancer, 1998. 83(11): p. 2400-7. [4]. Lee KI, et al. Etoposide induces pancreatic β-cells cytotoxicity via the JNK/ERK/GSK-3 signaling-mediated mitochondria-dependent apoptosis pathway. Toxicol In Vitro. 2016 Jul 26. pii: S0887-2333(16)30147-3. [5]. Cui D, et al. FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.Cell Rep. 2020 Jan 14;30(2):497-509.e4. |